High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection

Atherosclerosis

Volumn 201, Issue 2, 2008, Pages 434-439

  Guimarães, Milena Maria Moreira ^a   Greco, Dirceu Bartolomeu ^a   Figueiredo, Sônia Maria de ^a   Fóscolo, Rodrigo Bastos ^a   Oliveira Jr , Antônio Ribeiro de ^a   Machado, Lucas José de Campos ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antiretroviral therapy; C reactive protein; Cardiovascular disease; Cardiovascular risk; HIV; Metabolic syndrome

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD4 ANTIGEN; CHOLESTEROL; GLUCOSE; INSULIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ABDOMINAL FAT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VIRUS LOAD; WAIST HIP RATIO;

ADIPOSITY; ADULT; ANTHROPOMETRY; ANTI-RETROVIRAL AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 54749089616     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.02.003     Document Type: Article

References (28)

1. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
2. Currier J.S., Taylor A., Boyd F., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33 (2003) 506-512
3. Barbaro G., Di Lorenzo G., Cirelli A., et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25 (2003) 2405-2418
4. Vittecoq D., Escaut L., Chironi G., et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 17 suppl. 1 (2003) S70-S76
5. Bozzette S.A., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
7. Ridker P.M., Brown N.J., Vaughan D.E., Harrison D.G., and Mehta J.L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109 (2004) IV6-IV19
8. Henry K., Kitch D., Dube M., et al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 18 (2004) 2434-2437
9. Lai S., Lai H., Celentano D.D., et al. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS 17 (2003) 211-219
10. Masiá M., Bernal E., Padilla S., et al. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 195 (2007) 167-171
11. Leite C.C., Matsuda D., Wajchenberg B.L., Cerri G.G., and Halpern A. Correlação da medida de espessura intra-abdominal medida pela ultra-sonografia com os fatores de risco cardiovascular. Arq Bras Endocrinol Metabol 44 (2000) 49-56
12. Lukaski H.C. Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 46 (1987) 537-556
13. Durnin J.V., and Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32 (1974) 77-97
14. Armellini F., Zamboni M., Robbi R., et al. Total and intra-abdominal fat measurements by ultrasound and computerized tomography. Int J Obes Relat Metab Disord 17 (1993) 209-214
15. Radominski R.B., Hebroso D.P., Cerri G.G., and Halpern A. O uso da ultra-sonografia na avaliação da distribuição de gordura abdominal. Arq Bras Endocrinol Metabol 44 (2000) 5-12
16. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
17. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
18. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
19. Masiá M., Padilla S., Bernal E., et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther 29 (2007) 1448-1455
20. Santos A.C., lopes C., Guimarães J.T., et al. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes 29 (2005) 1452-1456
21. Patel D.A., Srinivasan S.R., Xu J.H., et al. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metabolism 55 (2006) 699-705
22. González A.S., Guerrero D.B., Soto M.B., et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 60 (2006) 802-809
23. Samaras K., Wand H., La M., et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III Criteria. Diabetes Care 30 (2007) 113-119
24. Palacios R., Santos J., González M., et al. Incidence and prevalence of metabolic syndrome in a cohort of näive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS 18 (2007) 507-508
25. Torres J.L., and Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 18 (2003) 471-478
26. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
27. Tall A.R. C-reactive reassessed. N Engl J Med 350 (2004) 1450-1452
28. Zietz C., Hotz B., Sturzl M., Rauch E., Penning R., and Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation and increased leukocyte adherence. Am J Pathol 149 (1996) 1887-1898